Study examines cost-effectiveness of medicare drug plans in schizophrenia and bipolar disorder

February 20, 2013, University of Pittsburgh Schools of the Health Sciences

A new study published online today in the American Journal of Managed Care found that in Medicare Part D, generic drug coverage was cost-saving compared to no coverage in bipolar disorder and schizophrenia, while also improving health outcomes. Researchers from the University of Pittsburgh School of Medicine, the Pitt Graduate School of Public Health, and Western Psychiatric Institute and Clinic of UPMC note that policymakers and insurers should consider generic-only coverage, rather than no gap coverage, to both conserve health care resources and improve health.

offers for Medicare beneficiaries and since the program's inception in 2006, many enrollees have benefited from improved drug coverage and increased medication use. However, a major concern is the large coverage gap in the standard Part D design, where beneficiaries pay 100 percent of out-of-pocket. About one-third of all Medicare beneficiaries enter this coverage gap each year, and once there, they often reduce medication use, which may lead to increases in hospitalization and medical spending.

"This coverage gap is an even larger concern for Medicare beneficiaries with severe mental disorders such as bipolar and schizophrenia," said Kenneth J. Smith, M.D., M.S., associate professor of medicine and clinical and translational science at the University of Pittsburgh, and lead author of the study. "Our cost-effectiveness analysis of Part D plans is an unconventional yet instructive way to inform managed care decision-making."

Added concerns for mental health patients include:

  • Mental health patients are much more likely to enter the "gap:" 62 percent of with and 56 percent of those with schizophrenia entered the gap in 2007.
  • If they discontinue psychotropic medications, they may relapse to more severe episodes and require .
  • They experience high rates of comorbid chronic physical conditions such as heart disease and diabetes, which can be exacerbated by untreated mental illness and increase morbidity, medical spending and mortality.
The standard Part D benefit in 2007 included four phases: (1) an initial $265 deductible; (2) a period in which beneficiaries paid 25 percent of drug costs between $265 and $2,400; (3) a coverage gap in which they paid 100 percent of costs between $2,401 and $3,850, where they reached their total out-of-pocket spending catastrophic limit; and (4) a catastrophic coverage period where they paid 5 percent of costs.

Although the standard Part D benefit includes these four phases, some companies offering Part D drug plans modified the design and offered either "actuarially equivalent" or enhanced plans. In 2007, for example, 72 percent of stand-alone Part D plans had the standard coverage gap, 27 percent offered coverage for generic drugs used in the gap, and fewer than 1 percent offered coverage for both brand-name and generic drugs.

"Our objective was to examine differences in health outcomes and costs between coverage groups in patients with bipolar disorder and schizophrenia," added Smith. "We were most interested in differences between the no-gap and generic coverage groups because policies governing the plans' availability and affordability could affect health costs and outcomes for beneficiaries entering the coverage gap."

Of the more than 180,000 patients with bipolar disorder and schizophrenia that were evaluated, 14.6 percent had no gap coverage, and 7.1 percent had generic coverage. The remainder had low-income subsidies with more generous coverage, and therefore, were not strictly comparable to the other two groups. When comparing the no-gap coverage and generic gap coverage groups, patients with generic coverage had better health outcomes and reduced total medical costs as follows:

  • In disabled recipients with bipolar disorder and no coverage, costs were $570 per person more than generic coverage ($25,090 annually for no gap coverage compared to $24,520 for generic coverage)
  • In an aged recipient with bipolar disorder and no coverage, costs were $563 more per year than generic coverage
  • In a disabled recipient with schizophrenia and no coverage, costs were $1,312 more per year than generic coverage
  • In an aged recipient with schizophrenia and no coverage, costs were $1,289 more per year than generic coverage
Costs were lower with generic coverage due to fewer hospitalizations when this coverage was in place. The authors conclude that generic coverage in the gap is cost-saving compared with no-gap coverage (the standard part D design) and improves .

Explore further: Medicare coverage gap associated with reductions in antidepressant use in study

Related Stories

Medicare coverage gap associated with reductions in antidepressant use in study

July 2, 2012
The Medicare Part D coverage gap was associated with reduced use of antidepressants in a study of beneficiaries 65 years or older with depression, according to a report by Archives of General Psychiatry.

Reducing drug funding to Medicare patients will lead many to stop taking their medications

August 16, 2011
The lack of financial assistance to cover the cost of drugs to Medicare beneficiaries (the US government's health insurance program for people aged 65 or over, which currently covers 50 million US citizens) could result in ...

Patients often stop taking heart drugs during Medicare coverage gaps

April 17, 2012
Patients who paid for heart medications solely through Medicare were 57 percent more likely to not take them during coverage gaps compared to those who had a Part D low-income subsidy or additional insurance, according to ...

Drug coverage of Medicare beneficiaries with kidney failure -- some surprising findings

March 8, 2012
The majority of Medicare beneficiaries with kidney failure participate in Medicare's Part D prescription drug coverage program, and most of these receive a low-income subsidy from the program, according to a study appearing ...

Recommended for you

Air pollution may shorten telomeres in newborns

January 24, 2018
A study conducted before and after the 2004 closure of a coal-burning power plant in Tongliang, China, found children born before the closure had shorter telomeres than those conceived and born after the plant stopped polluting ...

Number of older people with four or more diseases will double by 2035, say researchers

January 23, 2018
A study published today in Age and Ageing, the scientific journal of the British Geriatrics Society, reports that the number of older people diagnosed with four or more diseases will double between 2015 and 2035. A third ...

Placental accumulation of flame retardant chemical alters serotonin production in rats

January 22, 2018
A North Carolina State University-led research team has shown a connection between exposure to a widely used flame retardant chemical mixture and disruption of normal placental function in rats, leading to altered production ...

Marijuana use does not lower chances of getting pregnant

January 22, 2018
Marijuana use—by either men or women—does not appear to lower a couple's chances of getting pregnant, according to a new study led by Boston University School of Public Health (BUSPH) researchers.

Women run faster after taking newly developed supplement, study finds

January 19, 2018
A new study found that women who took a specially prepared blend of minerals and nutrients for a month saw their 3-mile run times drop by almost a minute.

Americans are getting more sleep

January 19, 2018
Although more than one in three Americans still don't get enough sleep, a new analysis shows first signs of success in the fight for more shut eye. According to data from 181,335 respondents aged 15 and older who participated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.